RNS Number : 8469D
Futura Medical PLC
11 September 2024
 

11 September 2024

 

Futura Medical plc

("Futura" or the "Company")

Trinity Delta research note and consensus forecasts

Futura Medical plc (AIM: FUM), the consumer healthcare company behind Eroxon®, that specialises in the development and global commercialisation of innovative and clinically proven sexual health products, announces the publication of an analyst report by Trinity Delta which is available on the Company's website: https://www.futuramedical.com/investor-centre/shareholder-centre/analyst-research/

 

Following the release of the updated research, the company confirms that the equity analyst consensus market expectations for revenue for the year ending 31 December 2024 and 31 December 2025 are £13.4 million and £18.6 million respectively.

 

Contacts:

Futura Medical plc

 

 

 

James Barder

Chief Executive Officer

Angela Hildreth

Finance Director and COO

 

investor.relations@futuramedical.com

+44 (0)1483 685 670

www.futuramedical.com

 

Panmure Liberum

Nominated Adviser

and Broker

 

Emma Earl, Will Goode, Mark Rogers (Corporate Finance)

Rupert Dearden (Corporate Broking)

+44 (0)20 3100 2000

 

 

 



Stifel Nicolaus Europe Limited

Joint Broker

 

Alan Selby

Ben Maddison

 

+44 (0)207 710 7600

 

 

 



Alma Strategic Communications

Rebecca Sanders-Hewett

Sam Modlin

Will Ellis Hancock

+44 (0)20 3405 0205

futura@almastrategic.com




 

Notes to Editors:

Futura Medical plc (AIM: FUM) is the developer of innovative sexual health products, including lead product Eroxon. Our core strength lies in our research, development and commercialisation of topically delivered gel formulations in sexual health products.

Eroxon, Futura's clinically proven lead product, has been developed for the treatment of Erectile Dysfunction ("ED"). The highly differentiated product, which is the only topical gel treatment for ED available over the counter and helps men get an erection in ten minutes, addresses significant unmet needs in the ED market.

ED impacts 1 in 5 men globally across all adult age brackets, with approximately half of all men over 40 experiencing ED and 25% of all new diagnoses being in men under 40.

Futura has distribution partners in place in a number of major consumer markets including Haleon in the US, the largest market for ED in the world, and Cooper Consumer Health in Europe. Eroxon has been nominated for a number of healthcare industry awards and has won two to-date.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCDZGMLVMZGDZM
Futura Medical (LSE:FUM)
Historical Stock Chart
From Oct 2024 to Nov 2024 Click Here for more Futura Medical Charts.
Futura Medical (LSE:FUM)
Historical Stock Chart
From Nov 2023 to Nov 2024 Click Here for more Futura Medical Charts.